XP-8121
Congenital Hyperinsulinism
Preclinical/Phase 1Investigation
Key Facts
Indication
Congenital Hyperinsulinism
Phase
Preclinical/Phase 1
Status
Investigation
Company
About Xeris Pharmaceuticals
Xeris Pharmaceuticals is a publicly traded company (NASDAQ: XERS) that has built a commercial portfolio and pipeline around its novel formulation technologies designed to eliminate reconstitution and enable room-temperature stability of injectable drugs. The company's strategy involves both developing its own products and partnering with other biopharma companies to reformulate their injectables. With three FDA-approved products on the market and a pipeline of reformulation candidates, Xeris aims to address significant unmet needs in endocrinology, neurology, and rare diseases.
View full company profileTherapeutic Areas
Other Congenital Hyperinsulinism Drugs
| Drug | Company | Phase |
|---|---|---|
| RM-718 | Rhythm Pharmaceuticals | Pre-clinical |
| XOMA 358 (RZ358) | XOMA | Phase 2 |
| Ersodetug | Rezolute | Phase 3 |